Literature DB >> 15897984

Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002.

Aisha O Jumaan1, Onchee Yu, Lisa A Jackson, Kari Bohlke, Karin Galil, Jane F Seward.   

Abstract

BACKGROUND: Varicella zoster virus (VZV) causes varicella and, later in the life of the host, may reactivate to cause herpes zoster (HZ). Because it is hypothesized that exposure to varicella may boost immunity to latent VZV, the vaccination-associated decrease in varicella disease has led some to suggest that the incidence of HZ might increase. We assessed the impact that varicella vaccination has on the incidence of varicella and of HZ.
METHODS: Codes for cases of varicella and of HZ in an HMO were determined in automated databases of inpatients and outpatients, on the basis of the Ninth Revision of the International Classification of Diseases. We calculated the incidence, during 1992-2002, of varicella and of HZ.
RESULTS: The incidence of HZ remained stable as the incidence of varicella decreased. Age-adjusted and -specific annual incidence rates of varicella decreased steadily, starting with 1999. The age-adjusted rates decreased from 2.63 cases/1000 person-years during 1995 to 0.92 cases/1000 person-years during 2002; among children 1-4 years old, there was a 75% decrease between 1992-1996 and 2002. Age-adjusted and -specific annual incidence rates of HZ fluctuated slightly over time; the age-adjusted rate was highest, at 4.05 cases/1000 person-years, in 1992, and was 3.71 cases/1000 person-years in 2002.
CONCLUSIONS: Our findings revealed that the vaccination-associated decrease in varicella disease did not result in an increase in the incidence of HZ. These early findings will have to be confirmed as the incidence of varicella disease continues to decrease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897984     DOI: 10.1086/430325

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  74 in total

1.  A pathway to leadership for adult immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on June 14, 2011.

Authors: 
Journal:  Public Health Rep       Date:  2012 Jan-Feb       Impact factor: 2.792

2.  Should varicella vaccine be included in the routine immunization programme?

Authors:  Hualiang Lin; Yu Liu; Linwei Tian
Journal:  Transl Pediatr       Date:  2014-10

3.  Trends in Nationwide Herpes Zoster Emergency Department Utilization From 2006 to 2013.

Authors:  Erica D Dommasch; Cara J Joyce; Arash Mostaghimi
Journal:  JAMA Dermatol       Date:  2017-09-01       Impact factor: 10.282

4.  Secular trends in the epidemiology of shingles in Alberta.

Authors:  M L Russell; D P Schopflocher; L Svenson; S N Virani
Journal:  Epidemiol Infect       Date:  2007-02-12       Impact factor: 2.451

Review 5.  Should the UK introduce varicella vaccine?

Authors:  Marion Roderick; Athimalaipet V Ramanan; Adam Finn
Journal:  Arch Dis Child       Date:  2007-11-08       Impact factor: 3.791

Review 6.  Herpes zoster.

Authors:  David W Wareham; Judith Breuer
Journal:  BMJ       Date:  2007-06-09

7.  Seven fatal varicella infections in children were potentially avoidable: A report from IMPACT centres from 2000 to 2005.

Authors:  David W Scheifele; Barbara Law; Scott A Halperin; Theresa Tam
Journal:  Paediatr Child Health       Date:  2006-09       Impact factor: 2.253

8.  Chronic medical conditions as risk factors for herpes zoster.

Authors:  Riduan M Joesoef; Rafael Harpaz; Jessica Leung; Stephanie R Bialek
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

9.  Severe complications of chickenpox in hospitalised children in the UK and Ireland.

Authors:  J C Cameron; G Allan; F Johnston; A Finn; P T Heath; R Booy
Journal:  Arch Dis Child       Date:  2007-11-08       Impact factor: 3.791

10.  Sociodemographic characteristics and chronic medical conditions as risk factors for herpes zoster: a population-based study from primary care in Madrid (Spain).

Authors:  María D Esteban-Vasallo; M Felicitas Domínguez-Berjón; Ruth Gil-Prieto; Jenaro Astray-Mochales; Angel Gil de Miguel
Journal:  Hum Vaccin Immunother       Date:  2014-05-07       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.